<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-252 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-252</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-252</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-5.html">extraction-schema-5</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-8015884</p>
                <p><strong>Paper Title:</strong> Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles</p>
                <p><strong>Paper Abstract:</strong> Introduction Triple-negative breast cancers (TNBCs) are characterised by lack of expression of hormone receptors and epidermal growth factor receptor 2 (HER-2). As they frequently express epidermal growth factor receptors (EGFRs), anti-EGFR therapies are currently assessed for this breast cancer subtype as an alternative to treatments that target HER-2 or hormone receptors. Recently, EGFR-activating mutations have been reported in TNBC specimens in an East Asian population. Because variations in the frequency of EGFR-activating mutations in East Asians and other patients with lung cancer have been described, we evaluated the EGFR mutational profile in tumour samples from European patients with TNBC. Methods We selected from a DNA tumour bank 229 DNA samples isolated from frozen, histologically proven and macrodissected invasive TNBC specimens from European patients. PCR and high-resolution melting (HRM) analyses were used to detect mutations in exons 19 and 21 of EGFR. The results were then confirmed by bidirectional sequencing of all samples. Results HRM analysis allowed the detection of three EGFR exon 21 mutations, but no exon 19 mutations. There was 100% concordance between the HRM and sequencing results. The three patients with EGFR exon 21 abnormal HRM profiles harboured the rare R836R SNP, but no EGFR-activating mutation was identified. Conclusions This study highlights variations in the prevalence of EGFR mutations in TNBC. These variations have crucial implications for the design of clinical trials involving anti-EGFR treatments in TNBC and for identifying the potential target population.</p>
                <p><strong>Cost:</strong> 0.013</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e252.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e252.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR_ethnic_variation_NSCLC</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Ethnic/geographic variation in EGFR-activating mutation prevalence in non-small-cell lung cancer (NSCLC)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper cites prior literature reporting substantial differences in the prevalence of EGFR-activating mutations between East Asian and non-Asian (European/American) patients with NSCLC, and notes this geographic/ethnic variation as established in the field.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not directly studied in this paper; the manuscript refers to prior studies of NSCLC cohorts from East Asian and non-Asian (European/American/Japanese) populations without giving a single pooled sample size or detailed breakdown.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_type</strong></td>
                            <td>EGFR-activating mutations typically cited: exon 19 deletions and L858R substitution in exon 21 (most common); rare exon 18 mutations; exon 20 mutations associated with resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_asian</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_non_asian</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_comparative_ethnic_data</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>patient_smoking_status</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Non-small-cell lung cancer (NSCLC); the paper also references lung adenocarcinoma in the context of ethnicity-specific genomic profiles.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>The authors mention the possible role of specific environmental carcinogenic factors in East Asia as a hypothesis to explain higher EGFR mutation frequencies, but do not specify particular agents within this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>The paper refers to ethnicity-specific genomic profiles and polymorphisms (citing prior work) as potential contributors to ethnic differences in EGFR mutation prevalence.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Hypothesised explanations include (1) differences in environmental carcinogenic exposures across geographic/ethnic groups and (2) inherited/genomic differences tied to ethnicity that influence somatic mutation spectra; no molecular mechanism is tested in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>odds_ratio_or_risk</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Differences in specimen processing and detection methods (e.g., fixation artefacts in paraffin-embedded tissues), cohort selection and geographic composition, and methodological sensitivity of mutation assays are discussed as alternative explanations or confounders.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>The authors note that ethnic/geographic differences in EGFR-activating mutation prevalence have been clearly shown in NSCLC literature and propose that similar ethnic/geographic variation may explain discrepant EGFR mutation frequencies reported in triple-negative breast cancer studies; however, this paper does not provide new quantitative lung-cancer ethnicity comparisons.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e252.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e252.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR_TNBC_ethnic_variation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR-activating mutation prevalence in triple-negative breast cancer across European and East Asian populations (used as evidence for ethnic/geographic variation)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>This paper reports 0% EGFR-activating (exon 19 deletion or exon 21 L858R) mutations in a European TNBC cohort (n=229) and contrasts that with a previously published East Asian (predominantly Chinese) TNBC series that reported 11.4% prevalence, using this contrast to argue for geographic/ethnic variation in EGFR mutation frequencies.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Primary data: 229 European TNBC patients (Val d'Aurelle Cancer Centre, France), frozen macrodissected invasive TNBC specimens; median age 58 years (range 29â€“84). The paper contrasts these data with previously published predominantly Chinese cohorts (Teng et al.) and other international series.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_type</strong></td>
                            <td>The study specifically screened for EGFR exon 19 deletions and the L858R substitution in exon 21; none were found in the 229 European TNBC samples. The contrasted East Asian report (Teng et al.) identified exon 19 deletions and exon 21 L858R mutations in their TNBC series.</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_asian</strong></td>
                            <td>Reported in referenced East Asian (predominantly Chinese) TNBC series: 11.4% (Teng et al., cited in this paper); other small Chinese series reported 1.4% in 139 breast cancers (including TNBC subset) per Lv et al. as discussed in the text.</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_non_asian</strong></td>
                            <td>European TNBC series in this paper: 0% activating EGFR mutations (0/229).</td>
                        </tr>
                        <tr>
                            <td><strong>has_comparative_ethnic_data</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>patient_smoking_status</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>Authors suggest that specific environmental carcinogenic factors in East Asia could contribute to higher mutation frequencies observed in some East Asian series, but no specific exposures are named or tested in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>Authors propose that ethnicity-specific genomic differences/polymorphisms and ancestry-specific genomic profiles (cited literature) may underlie observed differences in EGFR mutation prevalence between populations.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>The paper proposes geographic/ethnic variation driven by either environmental carcinogens prevalent in East Asia and/or underlying germline/genomic differences tied to ancestry as explanations for divergent EGFR mutation frequencies between cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>odds_ratio_or_risk</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Potential confounders discussed include methodological differences (assay sensitivity, use of frozen vs paraffin-fixed tissue), fixation artefacts producing false positives in paraffin-embedded samples, cohort composition differences (ethnicity, selection), and small sample sizes in some studies.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>In the largest European TNBC cohort screened to date (n=229), no classical EGFR-activating mutations (exon 19 deletions or L858R) were detected, in stark contrast to an 11.4% prevalence reported in a predominantly Chinese TNBC series; the authors interpret this discrepancy as evidence supporting geographic/ethnic variation in EGFR mutation prevalence and stress implications for selecting target populations in clinical trials.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. <em>(Rating: 2)</em></li>
                <li>Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. <em>(Rating: 2)</em></li>
                <li>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. <em>(Rating: 2)</em></li>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. <em>(Rating: 2)</em></li>
                <li>Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. <em>(Rating: 2)</em></li>
                <li>Genomic profiles specific to patient ethnicity in lung adenocarcinoma. <em>(Rating: 2)</em></li>
                <li>EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>